Human Genome Sciences (HGS), a medical science firm, has named David Southwell as executive vice president (EVP) and chief financial officer (CFO). He will report directly to Thomas Watkins, president and chief executive officer (CEO), and will serve as a member of the management committee. Southwell has served as a member of the HGS board of directors since July 2008, and he is resigning from the board to accept this new position.
Prior to joining the HGS board, Southwell was EVP and CFO at Sepracor, a research-based pharmaceutical company. During his fourteen-year tenure at Sepracor, Southwell advanced through a series of senior management positions with increasing responsibility in finance, corporate planning, development and licensing.
Prior to Sepracor, he was vice president, investment banking division, at Lehman Brothers in New York.
Southwell graduated from Rice University, and received his MBA from the Tuck School of Business at Dartmouth College. He serves as chairman of the board of directors for BioSphere Medical, and is a member of the board of directors of PTC Therapeutics. He also serves as chairman of the Tuck School of Business MBA Advisory Board.
UK firms investment in training and development will increase, on average, by a fifth in the next year, claims Robert Half recruitment after interviewing 100 financial services (FS) executives.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.